Neuroscience shifting from drugs to neural circuitry

09/23/2013 | Guardian (London), The

Pharmaceutical companies have reduced their investment in developing new psychiatric drugs as neuroscience increasingly focuses on the electrical activity of neural networks as a key to understanding and treating mental illness. For example, the U.S. National Institute of Mental Health is investigating how brain circuitry contributes to depression and schizophrenia, and Medtronic has pioneered deep brain stimulation for Parkinson's disease, epilepsy and addiction. The emerging field of optogenetics injects neurons with light-sensitive proteins for more precise treatments.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA